NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...